Vera Therapeutics VERA 深 滬
等待開盤 10-28 09:30:00 美东时间
29.99
+1.690
+5.97%
華盛通- 最 高30.02
- 今 開28.35
- 成交量 106.98万股
- 最 低 28.21
- 昨 收 28.30
- 總市值 21.61亿
- 52周最高 56.05
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 26.00
- 委 比 -91.68%
- 總股本 7206.33万
- 歷史最高 56.05
- 量 比 0.60
- 振 幅 6.40%
- 歷史最低 5.20
- 每 手 1
- 風險率 6.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks
Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy (IgAN) at risk for disease progression was presented as a featured late-breaking oral presentati...
10-22 22:06
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics announced that TRUTAKNA, the first FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints in the ORIGIN 3 trial for adults with primary IgA nephropathy (IgAN). The drug demonstrated favorable safety, with adverse events comparable to placebo, and a plan to submit a supplemental BLA in Q4 2026 for full approval in 2027. An investor webcast is scheduled for October 22.
10-22 14:05
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34
Leerink Partners analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Market Perform rating and announces Price Target of $34.
10-12 20:22
Most shorted stocks on Wall Street
As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of...
10-05 21:35
Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy
Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRU...
10-02 21:28
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Vera Therapeutics将在2026年美国肾脏学会肾脏周会议上展示关于TRUTAKNA和Atacicept在IgA肾病和原发性膜性肾病中的研究结果，包括ORIGIN 3试验的最终分析和PIONEER试验的中期数据，彰显其在自身免疫性肾脏疾病治疗方面的承诺。
10-02 13:24
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 400 points on Thursday. Shares of Vicor Corp (NASDAQ:VICR) rose sharply after the company announced it granted a non-exclusive license to a new OEM licensee with the right to procure Vertical Power Delivery modules by its patents from...
09-17 23:58
What's Going on With Vera Therapeutics Stock on Tuesday?
Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial. The study showed that Trutakna (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis ...
09-16 00:28
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
